For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales ...

The acquisition battle between global pharmaceutical giants Pfizer and Novo Nordisk over the bio company Metsera is heating ...

We recently published 10 Stocks With Easy 20-40% Gains. Metsera Inc. (NASDAQ:MTSR) is one of the last week’s best-performing stocks. Metsera saw its share prices jump by 20 percent week-on-week as ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

This out-of-favor drug maker is taking the steps needed to ensure it not only survives but thrives over the long term.

Metsera currently has no products on the market, but is developing oral and injectable treatments for obesity and diabetes.

Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the ...

Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

Pfizer files lawsuit against Metsera and its directors & Novo Nordisk in the Delaware Court of Chancery for breach of merger agreement: New York Monday, November 3, 2025, 09:00 Hr ...

Dow Jones Top Company Headlines at 1 AM ET: Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk | BDO's ... Novo Nordisk and Pfizer are showing some desperation in their gloves-off ...